P1696: ECONOMIC BURDEN IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) FOR PATIENTS WITH ≥2 PRIOR LINES OF THERAPY INCLUDING A BRUTON TYROSINE KINASE INHIBITOR (BTKI) AND/OR B-CELL LYMPHOMA 2 INHIBITOR (BCL2I)
oleh: Masoom Priyadarshini, Gaurav Deshpande, Simran K Tiwana, T. Kim Le, Sean Garrison, Farrukh Awan
| Format: | Article |
|---|---|
| Diterbitkan: | Wiley 2023-08-01 |
Deskripsi
No description available for this item.